title: Analysis of the kinetics of the parathyroid hormone, and of associated patient outcomes, in a cohort of haemodialysis patients.
abstract: Observational studies have recently associated a decrease in serum parathyroid hormone (PTH) level with a higher rate of mortality among hemodialysis (HD) patients. Decreases in PTH level can result from medical intervention (MPD) and surgical parathyroidectomy (PTX), or may occur spontaneously, usually associated with an underlying malnutrition-inflammation syndrome (SPD). The aim of our study was to prospectively identify the incidence of decreases in PTH level in a cohort of HD patients and the frequency distribution of the different causes (MPD, PTX and SPD), as well as to evaluate the survival outcomes for each PTH group (MPD, PTX and SPD) compared to patients who did not experience a PTH decrease over the first 36 months of the study (NPD).
  
  
  
  The 197 patients receiving HD at our center in January 2010, and meeting our eligibility criteria, were enrolled in our prospective study, and were observed for a period of 60 months. A decrease in PTH level >50 % between two successive PTH measurements obtained within an interval <3 months was defined as a significant event. MPD referred to a decrease in PTH due to an increased oral calcium intake, increased dialysate calcium concentration (DCC), increased alfacalcidol use, or use of cinacalcet therapy. A surgical 7/8 PTX was performed in young patients or in patients in whom cinacalcet therapy failed. SPD referred to a decrease in PTH related to a medical or surgical event. Baseline characteristics among patients in each group (MPD, PTX, SPD, and NPD) were evaluated using Fisher's exact test. The 60-month survival was evaluated using Kaplan-Meier and Cox multivariable proportional hazards models. Univariate and multivariate Cox analyzes were used identify variables with mortality. The relative risk of mortality was expressed as a hazard ratio (HR).
  
  
  
  The distribution of the 197 patients forming our four study groups was 34 % in the NPD group, 35 % in the SPD group, 25 % in the MSD group and 6 % in the PTX group. Among patients in the SPD group, the main acute comorbid conditions were peripheral vascular and cardiac complications, sepsis, fractures, and cancers with an increase in serum CRP level (from 14.3 ± 18 to 132 ± 90 mg/L) and a decrease in serum albumin (from 33 ± 4.5 to 28.6 ± 4 g/L). In the MPD group, the main therapeutic change was an increase in DCC, either independently or in association with cinacalcet therapy. The median survival rate among patients was 10 months for SPD, compared to 22 months among patients in the MPD group (p < 0.001). Using multivariable Cox model and taking the NPD group as reference, the risk of mortality was lower among patients in the MPD group (HR, 0.42[0.2-0.87] p = 0.01), with survival being comparable for the SPD and NPD groups (HR, 1.3 [0.75-2.2]). No mortality was observed in the PTX group.
  
  
  
  The poor outcomes associated with SPD, related to acute comorbid conditions, should not lead to undertreat secondary hyperparathyroidism whose appropriate medical or surgical therapies are associated with better outcomes.
authors.affiliation: NEPHROCARE Tassin-Charcot, 7, Avenue Maréchal FOCH, 69110, Sainte Foy-Les-Lyon, France. guillaume-jean-crat@wanadoo.fr.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Jean
authors.affiliation: Université Paris Descartes, Inserm U845, and Hôpital Necker, Service d'explorations fonctionnelles, Paris, France.
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Souberbielle
authors.affiliation: NOVESCIA Rhône-Alpes, Laboratoire du Grand Vallon, 69110, Sainte Foy-les-Lyon, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Zaoui
authors.affiliation: NEPHROCARE Tassin-Charcot, 7, Avenue Maréchal FOCH, 69110, Sainte Foy-Les-Lyon, France.
authors.forename: Christie
authors.initials: C
authors.lastname: Lorriaux
authors.affiliation: NEPHROCARE Tassin-Charcot, 7, Avenue Maréchal FOCH, 69110, Sainte Foy-Les-Lyon, France.
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Hurot
authors.affiliation: NEPHROCARE Tassin-Charcot, 7, Avenue Maréchal FOCH, 69110, Sainte Foy-Les-Lyon, France.
authors.forename: Brice
authors.initials: B
authors.lastname: Mayor
authors.affiliation: NEPHROCARE Tassin-Charcot, 7, Avenue Maréchal FOCH, 69110, Sainte Foy-Les-Lyon, France.
authors.forename: Patrik
authors.initials: P
authors.lastname: Deleaval
authors.affiliation: NEPHROCARE Tassin-Charcot, 7, Avenue Maréchal FOCH, 69110, Sainte Foy-Les-Lyon, France.
authors.forename: Manolie
authors.initials: M
authors.lastname: Mehdi
authors.affiliation: NEPHROCARE Tassin-Charcot, 7, Avenue Maréchal FOCH, 69110, Sainte Foy-Les-Lyon, France.
authors.forename: Charles
authors.initials: C
authors.lastname: Chazot
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002118:Calcium / Q000008:administration & dosage / Q000032:analysis; D000069449:Cinacalcet / Q000627:therapeutic use; D015314:Dialysis Solutions / Q000737:chemistry; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D007249:Inflammation / Q000097:blood / Q000150:complications; D007700:Kinetics; D008297:Male; D044342:Malnutrition / Q000097:blood / Q000150:complications; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood*; D016105:Parathyroidectomy; D011446:Prospective Studies; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy*; D015996:Survival Rate
chemical_list: D015314:Dialysis Solutions; D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D002118:Calcium; D000069449:Cinacalcet; C008088:alfacalcidol
keywords: Calcimimetics; Calcium; Haemodialysis; Parathyroid hormone; Parathyroidectomy; Survival rate; Vitamin D